Tumor size, grade, gender, age at diagnosis, and race appear to influence survival as prognostic factors in cutaneous pleomorphic sarcoma (CPS), according to a recent study. Furthermore, surgical tumor extirpation provides a survival benefit over no treatment whereas primary or adjuvant radiation does not provide a survival benefit. National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) data (1972-2013) were analyzed for 2,423 patients diagnosed with CPS. Researchers found:
- Age-adjusted incidence rate was 0.152 cases per 100,000 person-years and was 4.5-fold higher in males than females.
- Male gender, white race, and increasing age >40 years were significantly associated with decreased overall survival.
- Head and neck tumors, tumors >15mm, and with grade III or IV histology had significantly decreased survival.
- Surgical excision had a survival benefit compared to no treatment.
- Radiation therapy did not provide a survival benefit.
- Patients with localized disease had the greatest survival followed by regional and distant disease.
Ibanez, MA, Rismiller K, Knackstedt T. Prognostic factors, treatment, and survival in cutaneous pleomorphic sarcoma. [Published online ahead of print November 8, 2018]. J Am Acad Dermatol. doi:10.1016/j.jaad.2018.08.054.
Must Reads in Nonmelanoma Skin Cancer
Lymph Node Ratio and Survival Post-MCC Surgery, JAMA Dermatol; ePub 2019 Mar 2; Cheraghlou, et al
cSCC-HN Recurrence Post-Surgery Means Poor Survival, JAMA Dermatology; ePub 2019 Feb 27; Sun, Chin, et al
HLA Antigen Mismatch Linked with Skin Cancer Risk, JAMA Dermatology; ePub 2019 Jan 23; Gao, Twigg, et al
Health Care Screening, Skin Cancer Risk Link Found, JAMA Dermatology; ePub 2018 Dec 26; Drucker, et al